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Nearly all mammalian immune system mole-
cules found on the cell surface are glycosylated, 
including Toll-like receptors (TLRs), class I and II 
MHC proteins (MHCI and MHCII), CD1, 
and  TCRs. Complex asparagine (N)-linked 
glycans can reach 30 Å in length (Rudd et al., 
1999), which is comparable to the size of a 
protein Ig domain, and many of these surface 
glycoproteins have multiple sites of glycosyl-
ation. For molecules of the adaptive immune 
response (e.g., MHCII and TCRs), these glycans 
are thought to play three primary roles: a check 
point for proper protein folding and traffick-
ing to the cell surface (Bergeron et al., 1998; 
Trombetta and Helenius, 1998; Saito et al., 1999), 
protection of the protein backbone from pro-
teolysis once on the cell surface to maximize the 
lifetime of cell communication events (e.g., T cell 
activation; Wormald and Dwek, 1999), and pro-
motion of the appropriate geometric spacing of 
receptors and other molecules on the cell surface 
for optimized cell–cell attachment and com-
munication (e.g., the immune synapse; Dustin 
et al., 1997).
A central player in the adaptive immune re-
sponse is MHCII, which presents exogenous 
peptide antigens to TCRs on CD4+ T cells for 
recognition and T cell activation. The MHCII 
allele families carry two glycosylated asparagine 
residues that are highly conserved across species. 
For the human MHCII molecule HLA-DR2 
(DRA, DRB1*1501), there are three known 
glycosylated sites: N78, N118, and N103 (Fig. 1 A; 
Gauthier et al., 1998). Published findings dem-
onstrate that these glycans do not play a direct 
role in antigen binding or presentation, which 
is elegantly illustrated by crystal structures of 
nonglycosylated MHCII–peptide complexes ex-
pressed in bacteria (Frayser et al., 1999; Li et al., 
2000, 2001).
Recently, a new class of T cell–dependent 
antigens  has  been  described  that  includes   
capsular polysaccharides from types 5 and 8 
Staphylococcus  aureus  (Tzianabos  et  al.,  2001), 
type I Streptococcus pneumoniae (Sp1; Tzianabos 
et al., 1993; Stingele et al., 2004; Matsuda and 
Cepko., 2007; Velez et al., 2009), pneumococcal   
C-substance (Tzianabos et al., 1993), and polysac-
charide A (PSA) and polysaccharide B (Tzianabos 
et al., 1992, 1993, 1995) from the gut commen-
sal bacteria Bacteroides fragilis. Both Sp1 and PSA 
associate with MHCII molecules in professional 
APCs and are recognized by TCRs on CD4+  
T cells (Tzianabos et al., 1993; Cobb et al., 2004; 
Cobb and Kasper, 2008; Velez et al., 2009). 
Sp1 and PSA both form highly charged right-
handed helices with two repeating units per 
CORRESPONDENCE  
Brian A. Cobb: 
brian.cobb@case.edu
Abbreviations used: ME,  
-mercaptoethanol; BMDC, 
BM-derived DC; CS, castano-
spermine; GlyAg, glycoantigen; 
GM-CSF, granulocyte- 
macrophage colony-stimulating 
factor; IBD, inflammatory 
bowel disease; KF, kifunensine; 
MBPp, myelin basic protein 
peptide; PHA-L, Phaseolus vul-
garis leucoagglutinin; PSA, poly-
saccharide A; TLR, Toll-like 
receptor; UNT, untreated.
MHCII glycosylation modulates Bacteroides 
fragilis carbohydrate antigen presentation
Sean O. Ryan, Jason A. Bonomo, Fan Zhao, and Brian A. Cobb
Department of Pathology, Case Western Reserve University School of Medicine, Cleveland, OH 44106
N-linked glycans are thought to protect class II major histocompatibility complex (MHC) 
molecules (MHCII) from proteolytic cleavage and assist in arranging proteins within the 
immune synapse, but were not thought to directly participate in antigen presentation. 
Here, we report that antigen-presenting cells (APCs) lacking native complex N-glycans 
showed reduced MHCII binding and presentation of the T cell activating glycoantigen 
(GlyAg) polysaccharide A from Bacteroides fragilis but not conventional peptides. APCs 
lacking native N-glycans also failed to mediate GlyAg-driven T cell activation but activated 
T cells normally with protein antigen. Mice treated with the mannosidase inhibitor kifunen-
sine to prevent the formation of complex N-glycans were unable to expand GlyAg-specific 
T cells in vivo upon immunization, yet adoptive transfer of normally glycosylated APCs into 
these animals overcame this defect. Our findings reveal that MHCII N-glycosylation directly 
impacts binding and presentation of at least one class of T cell–dependent antigen.
© 2011 Ryan et al.  This article is distributed under the terms of an Attribution–
Noncommercial–Share Alike–No Mirror Sites license for the first six months after 
the publication date (see http://www.rupress.org/terms). After six months it is 
available under a Creative Commons License (Attribution–Noncommercial–Share 
Alike 3.0 Unported license, as described at http://creativecommons.org/licenses/
by-nc-sa/3.0/).
T
h
e
 
J
o
u
r
n
a
l
 
o
f
 
E
x
p
e
r
i
m
e
n
t
a
l
 
M
e
d
i
c
i
n
e1042 MHC class II glycosylation in presentation of glycoantigens | Ryan et al.
GlyAg-mediated T cell recognition and activation despite no 
detectable defects in peptide and intact protein antigen con-
trols. In contrast to the current model, our findings reveal that 
the nature of the N-glycans found on MHCII can directly 
modulate antigen binding and presentation. Because T cell rec-
ognition of GlyAg is critical for gut immune homeostasis 
(Mazmanian et al., 2005, 2008), these results raise intriguing 
questions about the variability of MHCII glycosylation in the 
gut (Barrera et al., 2002) and how inflammation-associated 
variability could modulate antigen presentation and T cell 
responses against the commensal microbiota.
RESULTS
Native MHCII N-glycans are required for GlyAg presentation
Although MHCII glycosylation does not appear to play a direct 
role in conventional peptide antigen binding (Frayser et al., 
1999; Li et al., 2000), we sought to determine the functional 
role of these glycan structures during commensal-derived 
GlyAg presentation. Human Raji B cells, which have been 
previously demonstrated to present GlyAg via MHCII bind-
ing (Cobb et al., 2004), were cultured in the presence and ab-
sence of the glucosidase inhibitor castanospermine (CS; 175 µM) 
or the mannosidase inhibitor kifunensine (KF; 10 µg/ml) for 
3 d to reduce the presence of hybrid and native complex 
turn and a pitch of 20 Å (Wang et al., 2000; Choi et al., 2002), 
whereas initial recognition of these “glycoantigens” (GlyAg) 
leads to cytokine production (e.g., IFN-) and T cell pro-
liferation (Brubaker et al., 1999; Stingele et al., 2004; Stephen 
et al., 2005) with an overall phenotype indistinguishable from 
T helper type I (TH1) cells. GlyAg association with HLA-DR2 
(DR2) shows high affinity (Kd = 315 nM; Cobb and Kasper, 
2008), is dependent on positive and negative charges found 
within the polysaccharide (Kreisman et al., 2007; Cobb and 
Kasper, 2008; Velez et al., 2009), and requires processing via 
nitric oxide to fragments in the 5–10 kD size range (Cobb et al., 
2004; Velez et al., 2009). Although GlyAg–MHCII binding is 
competitive with peptide antigens and requires the expression 
of HLA-DM in APCs for presentation (Cobb and Kasper, 
2008;  Velez et al., 2009), the manner in which GlyAgs interact 
with MHCII remains unknown.
Here, we present a study in which it was discovered that 
bacterially expressed DR2 failed to associate with GlyAg despite 
being properly folded and fully capable of binding to anti-
genic peptide. We also show that elimination of native com-
plex N-linked glycans (i.e., unaltered mammalian complex 
N-glycans) on MHCII reduced presentation of GlyAg in 
live APCs, nearly eliminates GlyAg binding to recombinant 
MHCII in vitro, and significantly limits in vitro and in vivo   
Figure 1.  HLA-DR2 glycosylation sites and mechanism. (A) HLA-DR2 (DRA; DRB1*1501), shown with myelin basic protein peptide (green; space-filling), 
contains three N-glycosylation sites. The N78 position is highly conserved across species and is located at one end of the canonical peptide-binding groove, 
which is comprised of -helices (blue) and a -sheet foundation (red). Coordinates are from Gauthier et al., 1998. (B) Simplified N-glycosylation pathway in 
mammalian cells, highlighting the sites of CS (glucosidase inhibitor) and KF (mannosidase inhibitor) action and the representative structures expected. The 
asterisk highlights a complex N-glycan example from public data via the Consortium for Functional Glycomics. Specifically, this structure was found expressed  
by murine RAW macrophages, has a mass of 5035.3 Daltons, and is available in the dataset for A. Merrill request #1689 (http://www.functionalglycomics.org/
glycomics/publicdata/glycoprofiling-new.jsp).JEM VOL. 208, May 9, 2011 
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the metabolic state of the cells were assessed by measuring 
ATP production (Fig. 2 E). No reduction in cellular metabolic 
activity (i.e., ATP production) was seen between UNT and 
inhibitor-treated cells. Finally, it has been previously reported 
that PSA and other GlyAgs require intracellular processing 
via a nitric oxide–dependent pathway. To ensure that the 
treated Raji B cells processed PSA normally, full-length ra-
diolabeled PSA was given to the cells, and then isolated from 
the endosomal compartments after overnight incubation. The 
endosomal PSA was then passed through an analytical molec-
ular sieve column to measure the molecular size. We found 
that all cells equally endocytosed and processed PSA into two 
molecular mass populations (Fig. 2 F, arrows) as previously 
published (Cobb et al., 2004).
CS- and KF-treated Raji B cells were also compared with 
UNT cells by confocal microscopy. The cells were given in-
hibitor for 3 d before incubation with either AlexaFluor594-
conjugated PSA (red) or DQ-OVA (shown in red), which is 
fluorescent  only  after  proteolytic  processing  into  peptides 
(Lewis and Cobb, 2010). After 24 h of antigen exposure, the 
cells were fixed with 4% paraformaldehyde, stained with   
Alexa Fluor 488– or Alexa Fluor 633–conjugated MHCII mAb 
(shown in green for both), and viewed by confocal micros-
copy (Fig. 3, A and C). We found no detectable 
difference in MHCII staining as a function of 
drug treatment. In addition, the presence of 
bright DQ-OVA signal at the cell surface in-
dicates that there was no significant difference 
in OVA processing or surface localization. In 
contrast, a reduction in surface colocalization 
of PSA in cells treated with CS or KF (lack of 
yellow colocalization signal in overlay images) 
was observed. Using a series of images (n = 8), 
we analyzed the pixel intensity distribution 
within each cell for each antigen. We found 
highly significant reductions (P < 0.01) in 
N-glycans on cellular glycoproteins (Fig. 1 B). On the fourth 
day, the cells were provided fresh drug and either biotinylated 
myelin basic protein peptide (MBPp) or biotinylated glyco-
antigen PSA from B. fragilis and allowed to incubate for an-
other 24 h. The MHCII-antigen complexes were subsequently 
immunoprecipitated with mAb against MHCII (clone L243) 
and probed with streptavidin to quantify the presented anti-
gen. We found no difference in the amount of MBPp pre-
sented by the cells treated with either inhibitor (Fig. 2, A and B) 
when compared with untreated cells (UNT), yet cells treated 
with CS or KF showed significant reductions in the amount 
of GlyAg presented (Fig. 2, A and B).
Given that CS and KF affect all N-glycosylated proteins 
in the cell, we used identically treated Raji B cells in flow cyto-
metry experiments to measure surface-localized MHCII mole-
cules. No difference was detected in the surface concentration 
of MHCII (Fig. 2, C and D). We also used FITC-conjugated 
lectins to stain the cells and found the expected reductions in 
Phaseolus vulgaris leucoagglutinin (PHA-L), PHA-E, and WGA 
lectin staining with concomitant increases in Con A staining 
in CS- and KF-treated populations (Fig. 2, C and D), suggest-
ing that the glycans present had increased mannose composi-
tions. To ensure that CS and KF did not affect cell viability, 
Figure 2.  B cells lacking native N-glycans show 
reduced PSA presentation. (A and B) Coimmuno-
precipitations (coIP) with -MHCII mAb from CS- and 
KF-treated Raji B cells show reduced PSA (CS, P < 0.001; 
KF, P < 0.01), but not MBP peptide (P > 0.05), presentation 
compared with untreated (UNT) controls. n = 12 for all 
PSA; n = 15 for all MBPp. (C and D) Flow cytometry of 
UNT, CS-treated (C), and KF-treated (D) Raji B cells using 
lectin staining to detect the glycophenotype of the cell 
surface. Representative histograms are shown; n = 4 for 
each data point. (E) ATP production of UNT, CS-treated, 
and KF-treated Raji B cells. n = 3 for each data point.  
(F) [3H]-labeled PSA isolated from endosomal compart-
ments was analyzed from UNT, CS-treated, and  
KF-treated Raji B cells and compared with intact,  
full-length PSA control (PSA cont.) by size exclusion 
HPLC using a Superose 12 column. The arrow indicates 
low molecular mass PSA. Representative elution profiles 
are shown. All bar graphs show the mean ± SEM.1044 MHC class II glycosylation in presentation of glycoantigens | Ryan et al.
native complex N-glycans on all proteins expressed by the 
cells (Fig. 4, A and B). To better characterize the N-glycans 
present on the purified DR2 samples, a panel of lectins was 
used in ELISA assays. CS-DR2, KF-DR2, and UNT-DR2 
were captured in wells precoated with L243 mAb and then 
probed with FITC-conjugated lectins to quantify the types of 
glycans present in the DR2 samples (Fig. 4, C and D). We 
found no change in succinylated WGA (S-WGA) binding 
and  increased  Con A  binding,  but  reductions  in  PHA-L, 
WGA, GSL I, STL, and UAE I lectin binding for CS-DR2 
and KF-DR2 compared with UNT-DR2. These data indi-
cate significant modification of native N-glycans (PHA-L), 
fucosylation (UAE I), -linked galactose residues (GSL I), and 
terminal sialic acids (WGA and STL). The retention of S-WGA 
binding suggests that GlcNAc residues, which are found in 
the early core glycan structures (Fig. 1 B), remain. Likewise, 
the increased Con A staining demonstrates retention of man-
nose and/or glucose residues, typical of early core structures, 
within the glycans. Overall, the lectin screen demonstrates 
that the recombinant CS-DR2 and KF-DR2 lack the native 
complex N-glycans found in UNT-DR2.
MHCII binding to GlyAg requires both the protein backbone 
and native complex N-glycans
Bacteria-expressed  nonglycosylated  DR2  (Bac-DR2)  and 
CHO-expressed UNT-DR2 were used in quantitative binding 
assays with 10 µg/ml biotinylated MBPp or biotinylated low 
surface-localized PSA (Fig. 3 B), but not DQ-OVA (Fig. 3 D) 
signal in CS- and KF-treated cells compared with UNT, but 
little difference seen within the cells (Fig. 3, B and D).
The results shown in Figs. 2 and 3 collectively demonstrate 
that modification of N-glycans on MHCII proteins in human 
B cells reduces MHCII-dependent presentation of GlyAg, but 
not conventional peptide or intact protein antigens, and that 
this alteration is not caused by changes in cell viability, MHCII 
expression or trafficking, or GlyAg processing.
CS and KF reduce native complex N-glycans in Chinese 
hamster ovary (CHO) cells expressing recombinant HLA-DR2
Defects in GlyAg presentation within the context of live APCs 
could result from several processes that may be altered with CS 
and KF treatment, such as defects in HLA-DM activity or 
cathepsin activity to cleave the invariant chain (Ii) from the 
MHCII complex. To determine whether the observed defect 
was caused by deficiencies in GlyAg binding to MHCII,   
recombinant HLA-DR2 (DR2) was expressed in CHO cells in 
the presence and absence of CS and KF. The UNT, CS, and KF 
grown DR2 molecules (UNT-DR2, CS-DR2, and KF-DR2) 
were purified to homogeneity using an L243 mAb affinity 
column as previously described (Cobb et al., 2004).
To confirm the effectiveness of CS and KF, the CHO cells 
were analyzed by fluorescent lectin staining and flow cytom-
etry. In both cases, CS and KF significantly reduced PHA-L 
binding to the cell surface, demonstrating the elimination of 
Figure 3.  B cells lacking native N-glycans show internal but not surface MHCII-PSA colocalization. (A and B) Uptake of PSA (red) in UNT,  
CS-treated, and KF-treated Raji B cells. Intracellular colocalization with MHCII protein (green) is shown in yellow. (C and D) DQ-OVA was used as an intact 
protein antigen control, which fluoresces only after proteolytic cleavage (Lewis and Cobb, 2010). Representative images are shown; Bars, 10 µm. n = 8 for 
quantification. All bar graphs show the mean ± SEM.JEM VOL. 208, May 9, 2011 
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charges for MHCII binding (Kreisman et al., 2007; Cobb and 
Kasper, 2008), we treated UNT-DR2 with neuraminidase to 
remove negatively charged terminal sialic acids. Lectin ELISA 
confirmed the reduction of sialic acids (Fig. 4 H) and the 
neuraminidase-digested protein antigen binding was com-
pared with the binding to native UNT-DR2 (Fig. 4 I). We 
found a small, but statistically insignificant, change in overall 
binding of both GlyAg and conventional peptide, demon-
strating that the negative charges provided by terminal sialic 
molecular weight PSA as previously described (Cobb et al., 
2004; Cobb and Kasper, 2008). We found that PSA binding to 
Bac-DR2 was significantly reduced compared with the fully 
glycosylated UNT-DR2, whereas the binding of MBPp 
increased with the Bac-DR2 (Fig. 4 E). We also compared 
UNT-DR2  with  CS-DR2  and  KF-DR2  and  found  no 
change in conventional peptide antigen binding, but a 75% 
reduction in GlyAg binding (Fig. 4, F and G). Because PSA 
is a highly charged antigen that is known to depend upon 
Figure 4.  Both native N-glycans and the HLA-DR2 protein backbone are required for PSA binding. (A and B) Flow cytometry analysis of  
CS- and KF-treated CHO cells were compared with UNT cells using a lectin sensitive to the presence of native complex N-glycans. Representative histograms 
are shown. (C and D) HLA-DR2 expressed by UNT, CS-treated, and KF-treated CHO cells was immobilized and probed using a panel of FITC-conjugated 
lectins to detect changes in MHCII glycosylation. The raw data showing relative concentrations of the target glycan structure (D) and fold change (E) of 
each lectin is shown. n = 9 per data point. (E) Quantitative binding experiments using PSA or MBPp with purified HLA-DR2 expressed in bacteria (Bac-DR2; 
nonglycosylated) or DR2 expressed in CHO cells (CHO-DR2; fully glycosylated). n = 4 per data point. (F and G) MBPp and PSA binding to DR2 lacking  
native N-glycans expressed in CHO cells grown in CS-supplemented (n = 9; F) or KF-supplemented media (n = 18; G) compared with CHO-DR2 expressed 
in the absence of inhibitor. (H) Lectin ELISA of neuraminidase-digested CHO-DR2. (I) Native CHO-DR2 enzymatically trimmed with (2→3,6,8,9)- 
neuraminidase (NA-DR2) binding to PSA or MBPp compared with untreated CHO-DR2. n = 21. (J) Alexa Fluor 488–conjugated PSA was used as ligand in a 
glycan-binding array containing 320 glycans (Table S1) at the Consortium for Functional Glycomics. Positive signal is typically above 20,000 U. n = 4 per 
glycan. All bar graphs show the mean ± SEM.1046 MHC class II glycosylation in presentation of glycoantigens | Ryan et al.
Native complex N-glycans are required for GlyAg-mediated 
T cell activation in vitro
BM-derived DCs (BMDCs) were cultured for 3 d with and 
without CS or KF, as performed with the Raji and CHO 
cells. Fluorescent lectin staining analyzed by flow cytometry 
verified the loss of native complex N-glycans on CS- and 
KF-treated cells (Fig. 5 A) and the cells were confirmed as 
CD11c+ by flow cytometry (Fig. 5 B). On day 4, the cells 
were provided fresh drug and pulsed with 50 µg/ml PSA 
or 50 µg/ml OVA peptide (OVAp; residues 323–339) and 
20 ng/ml LPS, 20 ng/ml LPS alone, 50 µg/ml DQ-OVA,   
50 µg/ml Sp1, 50 µg/ml B. fragilis capsule containing polysac-
charide B, or no antigen for 24 h. DQ-OVA is intact OVA 
that is nonfluorescent until cleaved to peptide, thus aliquots of 
the DQ-OVA–pulsed cells were analyzed by flow cytometry 
to verify protein uptake and processing. No difference was 
seen between UNT, CS-, and KF-treated BMDCs (Fig. 5 C). 
acid residues are not critical for binding, yet native complex 
N-glycans are necessary for GlyAg but not conventional pep-
tide antigen binding to MHCII molecules.
The binding results suggest that GlyAg molecules may form 
carbohydrate–carbohydrate interactions with MHCII N-glycans. 
To determine whether GlyAg can bind to glycans independently 
from the MHCII protein backbone, Alexa Fluor 488–conjugated 
PSA was screened for binding against a library of 320 glycans at 
the Consortium for Functional Glycomics (Fig. 4 J). We found 
no significant interactions above background with any of the 
immobilized glycans (see Table S1 for a complete list).
These binding results directly demonstrate that the reduc-
tion in MHCII-dependent cell surface presentation of GlyAg 
is caused by defects in the direct interaction between GlyAg 
and MHCII. Furthermore, it is clear that neither the MHCII 
protein backbone nor the N-glycans are independently suffi-
cient for GlyAg binding.
Figure 5.  Native complex N-glycans are required for PSA-driven T cell activation in vitro. (A) BMDCs were cultured in the presence or absence 
of CS (red) and KF (blue) for 3 d, and then analyzed by PHA-L, PHA-E, WGA, and Con A lectin flow cytometry to detect N-glycans. Representative histo-
grams and n = 4 MFI analyses are shown. (B) BMDCs were cultured for 8 d, probed with CD11c mAb, and analyzed by flow cytometry to verify proper  
DC cell differentiation. Representative histogram is shown. (C) BMDCs were incubated with nonfluorescent intact DQ-OVA protein for 24 h to allow uptake 
and processing. Cells were then analyzed for fluorescence, which is indicative of endocytosis and cleavage to peptides. Representative histograms are 
shown. n = 4 for MFI analyses. (D) BMDC maturation upon exposure to antigen was measured by surface staining of MHCII 24 h after stimulation with 
OVA peptide and LPS (O+L), LPS alone, or PSA. Representative histograms shown. (E) BMDCs grown with and without CS and KF were pulsed with either 
DQ-OVA (OVA), OVAp+LPS (O+L), or LPS alone for 24 h, after which untreated fresh naive CD4+ T cells isolated from OT-II animals were added. n = 3 per 
condition, per antigen. (F) As with OVAp, BMDCs were grown with CS and KF and pulsed with PSA, Sp1, or B. fragilis capsule (Caps) for 24 h. Next, naive 
WT C57BL/6 CD4+ T cells were added to allow activation to occur. n = 3 per condition. (G) TLR2 activation by PSA, a necessary step in GlyAg-mediated  
T cell activation (Wang et al., 2006), and a control agonist Pam3Cysk4 (P3C) was measured in untreated (UNT), CS-treated, or KF-treated TLR2+ HEK293 
cells. Bars represent background-subtracted values. n = 3 per condition. All bar graphs show the mean ± SEM.JEM VOL. 208, May 9, 2011 
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and absence of CS and KF as before. On day 4, the cells were 
stimulated for 12 h with either 50 µg/ml PSA or 15 nM Pam-
3Cysk4 and culture supernatants assayed for IL-8 by ELISA 
(Fig. 5 G). We found robust IL-8 production in response to 
both stimuli and no change in IL-8 production in CS- or   
KF-treated cells.
Collectively, these data demonstrate that alterations in   
N-glycan formation in APCs does not affect conventional 
protein or peptide antigen–mediated T cell activation, but sig-
nificantly reduces T cell activation by three different GlyAgs.
Native complex N-glycans are required for GlyAg-mediated 
responses in vivo
Reduction of MHCII binding and presentation of GlyAg 
negatively effects in vitro T cell recognition and activation. To 
determine the in vivo effect of the reduction of native com-
plex N-glycans in C57BL/6 mice on GlyAg-mediated re-
sponses, animals were injected with 250 µg of KF daily for 1, 
2, or 3 d. On day 4, the animals were sacrificed and the bulk 
splenocytes were assessed by lectin (PHA-L) staining and flow 
cytometry to test for drug effectiveness (Fig. 6 A). We found 
that by day 3, essentially all native complex N-glycans were 
missing from the surface of all splenocytes.
To assess the effect of the 3-d KF treatment regimen on 
GlyAg-driven immune responses, we challenged the KF and 
PBS vehicle–treated (UNT) mice with PSA. After 6 d, the spleens 
were removed and the cells stimulated with PMA/ionomycin 
A subset of these antigen-pulsed BMDCs were also surface 
stained with FITC-conjugated MHCII mAb to measure 
increases in plasma membrane–localized MHCII concomi-
tant with DC maturation (Fig. 5 D). For all antigen combina-
tions, we found equal increases in surface MHCII localization 
over no antigen controls, thus neither CS nor KF leads to a 
defect in DC maturation. In fact, KF treatment appears to 
have increased the MHCII surface concentration above no-
inhibitor controls.
The  remaining  antigen-pulsed  BMDCs  were  cultured 
with fresh CD4+ T cells from either WT C57BL/6 (PSA, Sp1, 
and capsule assays) or OT-II (DQ-OVA and OVAp assays) 
mice to determine the capacity of the BMDCs loaded with 
antigen to induce T cell activation. At day 3 for DQ-OVA and 
OVAp assays (Fig. 5 E) or day 4 for the GlyAg assays (Fig. 5 F), 
culture supernatants were assessed for IFN- production by 
ELISA. We found no significant difference in OT-II T cell ac-
tivation between treatment groups when stimulated with in-
tact protein antigen DQ-OVA or preprocessed OVAp-pulsed 
BMDCs, yet all three GlyAg-mediated T cell activation assays 
were  significantly  reduced  in  assays  containing  BMDCs 
grown in CS or KF.
Previous findings have reported that GlyAg-mediated   
T cell activation requires signaling through TLR2 (Wang et al., 
2006). To rule out TLR2 as the cause of the lack of T cell   
activation mediated by GlyAg-pulsed and CS- or KF-grown 
BMDCs, we cultured TLR2+ HEK293 for 3 d in the presence 
Figure 6.  Native complex N-glycans are required for PSA-driven immune responses in vivo. (A) WT C57BL/6 animals (n = 8) were treated daily 
for 1, 2, or 3 d with 250 µg of KF, and then sacrificed to harvest splenocytes. Cells were stained for native complex N-glycans using PHA-L. Representative 
histogram shown. (B) WT mice (n = 3 per group) were treated with KF or PBS for 3 d, as in A. Animals were then sensitized with 100 µg PSA. Splenocytes 
were harvested 6 d later, stained for IFN- and CD4, and analyzed by flow cytometry. (C) KF- or PBS-pretreated mice (n = 6) were sensitized with 100 µg 
OVA and sterile cecal content adjuvant. 4 d later, CD4+ T cells were isolated and restimulated ex vivo with normally glycosylated APCs and OVA (n = 6).  
(D) Animals (n = 6) were treated as in C, only with 100 µg of PSA rather than OVA. The PSA-specific recall (n = 18) was measured after ex vivo restimula-
tion with normally glycosylated APCs and PSA. (E) Animals (n = 6) were treated as in D, only with the additional adoptive transfer of 5 × 106 fresh nor-
mally glycosylated APCs at the time of PSA injection (n = 12). For panels C–E, data were normalized to the antigen-sensitized animals without KF. All bar 
graphs show the mean ± SEM.1048 MHC class II glycosylation in presentation of glycoantigens | Ryan et al.
MGat2 ablation reduces native complex N-glycans  
and eliminates GlyAg-mediated T cell activation
Loss of the GlcNAc glycosyltransferase II enzyme (encoded 
by the MGat2 gene) in an animal model of the type IIa con-
genital disorders of glycosylation (CDG-IIa) results in several 
osteogenic, hematologic, and gastrointestinal tract abnormali-
ties (Wang et al., 2001). The mice lacking MGat2 also die 
early in postnatal development and lack native branched 
complex N-glycans. To determine if genetic-based loss of 
native complex N-glycans in the APC would also result in 
GlyAg T cell activation defects, BM was isolated from mice 
that carry the MGat2 gene flanked by LoxP sites but do not 
express the CRE recombinase. BM cells from either WT or 
MGat2flox animals were either mock electroporated or electro-
porated with an expression construct for myc-tagged CRE 
recombinase (pCRE) to excise the floxed MGat2 gene, and 
then cultured as usual with granulocyte-macrophage colony-
stimulating factor (GM-CSF) to derive dendritic cells. The 
four resulting populations of BMDCs were analyzed by PHA-L   
staining to confirm reduction in native complex N-glycans 
(Fig. 7 A). Approximately 40% of the MGat2flox BMDCs 
electroporated with pCRE lacked significant PHA-L stain-
ing, whereas the mock transfected MGat2flox BMDCs and 
both WT  populations  were  uniformly  PHA-L  positive.   
Unstained controls are shown in Fig. S1 A. NP-40 lysates from 
these four populations were analyzed using Western blots and 
probed with either anti-CRE (Fig. 7 B) or anti-myc (Fig. S1 B) 
antibodies to demonstrate CRE expression. Both WT and 
MGat2flox cells show CRE expression when electroporated 
for intracellular cytokine analysis. We found a significantly 
higher percentage of CD4+ T cells producing IFN- in ani-
mals expressing native complex N-glycans compared with 
animals treated with KF (Fig. 6 B).
To verify that this increase in CD4+IFN+ T cell number 
reflects PSA-specific cells, we performed recall experiments 
from UNT and KF-treated animals sensitized with PSA or 
OVA protein. Animals were injected with KF or PBS vehicle 
for three consecutive days. On the fourth day, the animals 
were challenged with OVA protein or PSA and allowed to 
respond for 4–6 d. The CD4+ T cells were then harvested 
from each animal and restimulated ex vivo with APCs from 
UNT naive animals (i.e., normally glycosylated cells) and either 
PSA or OVA to measure the level of immunological recall. 
We found that with OVA, the number of responding T cells 
during sensitization in KF-treated animals increased over 
animals sensitized without KF (Fig. 6 C). In contrast, KF treat-
ment during sensitization with PSA resulted in a decreased   
T cell response upon recall with PSA compared with UNT 
animals expressing native complex N-glycans (Fig. 6 D). These 
data show that KF inhibited PSA-specific T cell expansion 
during in vivo sensitization. To determine if this inhibition is 
caused by presentation defects within the resident APCs,   
KF-treated or UNT animals were sensitized with PSA along 
with adoptively transferred normally glycosylated APCs iso-
lated from naive mice. Inclusion of normal APCs during PSA 
sensitization of KF-treated animals allowed for PSA-specific 
T cell responses in vivo to reach normal levels, as shown by 
the increased PSA-specific recall response (Fig. 6 E).
Figure 7.  Deletion of MGat2 results in deficient PSA, but not OVA-mediated T cell activation. (A) BM cells were harvested from MGat2wt (WT) 
or MGat2flox animals, electroporated with a CRE expression construct (pCRE) or mock electroporated without DNA, and cultured with GM-CSF for DC dif-
ferentiation. Cells were stained with PHA-L to determine the effect of MGat2 excision. Representative histograms are shown. (B) Mock and pCRE electro-
porated BM cells were extracted and lysates were analyzed by anti-CRE Western blot using -actin as a loading control. Representative blot shown.  
(C) PHA-L pCRE electroporated MGat2flox BMDCs were isolated from PHA-L+ cells by negative selection using PHA-L and magnetic beads and compared 
with PHA-L+ pCRE-electroporated WT cells. Flow cytometry was used to measure the purity and glycophenotype of the populations, whereas RT-PCR on 
mRNA isolated from the PHA-Lpos and PHA-Lneg BMDCs was performed to demonstrate the excision of MGat2 in PHA-Lneg BMDCs (MGat2neg) but not 
PHA-Lpos BMDCs (MGat2pos). Representative histograms and gel shown. (D) Flow cytometry was used to measure BMDC differentiation (CD11c) and MHCII 
expression (MHCII) in both PHA-Lpos and PHA-Lneg BMDC populations. Representative histograms shown. (E) MGat2pos and MGat2neg BMDCs were cultured 
with either OT-II CD4+ T cells and OVA (50 µg/ml) or WT CD4+ T cells and PSA (50 µg/ml). T cell activation was determined by IFN- ELISA of the culture 
supernatants. (n = 3 independent experiments).JEM VOL. 208, May 9, 2011 
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adhesion molecules is even thought to contribute to the 
stability and avidity of the immune synapse formed between 
APCs and T cells, however, the fundamental binding proper-
ties of MHC for peptides and TCRs for the MHC-peptide 
complex are essentially unaffected by the presence or absence 
of complex N-glycans. In our studies, we even found that with 
bacteria-expressed nonglycosylated MHCII, peptide binding 
was increased over the glycosylated form. Although the 
mechanism for this increase remains unclear, many biochemi-
cal and structural studies on MHC and TCRs have used bacte-
rially expressed protein (Frayser et al., 1999; Li et al., 2000) or 
baculovirus/insect cell–expressed molecules (Brown et al., 
1995; Gauthier et al., 1998) that are characterized by regular, 
but limited, mannose core structures that lack mammalian 
complexity and heterogeneity (Altmann et al., 1999). In 
stark contrast to the wealth of information on conventional 
peptide antigens, our findings point to a fundamental yet 
poorly understood difference in the mechanism of interaction   
between carbohydrate antigens and MHCII in that the native 
complex N-glycans appear to play a critical functional role 
during association.
Another function of N-linked glycans is a check on pro-
tein folding within the endoplasmic reticulum. The addition 
of the core GlcNAc2Man9Glc3 N-glycan to asparagine resi-
dues within the Asn-X-Ser/Thr consensus sequence occurs 
in the ER. After the initial cleavage of two terminal glucose 
residues, these structures bind to calnexin and calreticulin, which 
are thought to be an important check on folding and facilitate 
MHCII trafficking out of the ER into the Golgi apparatus 
(Trombetta and Helenius, 1998). However, at least one study 
reported that treatment of APCs with the N-glycosylation 
inhibitor tunicamycin failed to alter the plasma membrane 
concentration of MHCII (Hart, 1982), suggesting that MHCII 
trafficking to the cell surface is not particularly sensitive to 
N-linked glycosylation. Indeed, our results support this inter-
pretation in that modification of the N-glycans on MHCII 
by blocking early steps in the glycosylation pathway did not 
alter MHCII surface staining or peptide presentation, yet 
GlyAg presentation was significantly reduced. Unaltered pep-
tide presentation and T cell activation in vitro demonstrate 
that the MHCII on the cell surface is properly folded and can 
be normally recognized by cognate TCRs on opposing CD4+ 
T cells. In vitro binding experiments with MHCII lacking 
native N-glycans reveal no reduction in peptide binding, but 
near ablation of GlyAg binding. Confocal microscopy further 
demonstrates vesicular colocalization of GlyAg and MHCII, 
confirming that antigen endocytosis and trafficking to the 
normal MHCII compartment was unaffected by the glyco-
sylation changes. Finally, structural studies using bacterial 
(Frayser et al., 1999; Li et al., 2000) and insect cell expressed 
MHCII (Brown et al., 1995; Gauthier et al., 1998) show no 
significant differences in overall structure. We conclude that 
although modification of N-glycans directly impacts GlyAg-
mediated responses and APC surface localization of GlyAg, 
this alteration in MHCII antigen presentation activity is not 
caused by changes in endocytosis, vesicular trafficking, surface 
with the pCRE but not in mock controls. Using biotinylated 
PHA-L, the PHA-L BMDCs were then isolated by mag-
netic bead negative selection, reanalyzed for PHA-L staining, 
and  compared  with  pCRE-electroporated WT  BMDCs 
(Fig. 7 C). The purity of each population was consistently >90% 
for both PHA-Lneg and PHA-Lpos BMDCs. mRNA was 
isolated from the two populations, and the lack of MGat2 tran-
script in the PHA-Lneg population was confirmed by RT-PCR 
(Fig. 7 C). As before, the expression levels of CD11c and   
MHCII were verified and no significant differences were ob-
served (Fig. 7 D). Finally, the MGat2pos and MGat2neg BMDCs 
were used in T cell activation assays with either OT-II CD4+ 
T cells (OVA assays) or WT CD4+ T cells (PSA assays). As 
seen with the CS- and KF-treated BMDCs (Fig. 5), the pro-
tein antigen response was unaffected by the loss of MGat2, yet 
the GlyAg response was nearly eliminated when native com-
plex N-glycans were missing in the BMDCs (Fig. 7 E). These 
data validate the inhibitor-based observations and confirm 
that PSA presentation and downstream T cell activation relies 
upon native complex N-glycosylation of MHCII proteins.
DISCUSSION
Most immune cell surface receptors and accessory molecules 
are glycoproteins, including CD4, CD8,  T cell receptors, 
and both class I and class II MHC. MHCII-dependent antigen 
presentation is a central event for adaptive immune responses 
against extracellular fungi, bacteria, and other pathogens. In 
this study, modification of MHCII N-glycosylation with   
N-glycosylation processing enzyme inhibitors (CS or KF) or 
through CRE-mediated ablation of the MGat2 gene resulted 
in the elimination of native complex N-glycans on APCs, 
which significantly reduced binding, presentation, and T cell 
activation by the glycoantigen PSA isolated from the capsule 
of the commensal bacteria B. fragilis. The reduction in presen-
tation translated into a reduction in GlyAg-mediated CD4+ 
T cell activation in vitro and in vivo. These findings demon-
strate for the first time that MHCII-mediated binding and 
presentation of at least one class of antigens depends heavily 
upon native complex N-glycans decorating the MHCII pro-
tein backbone.
Complex N-glycans are large and highly flexible struc-
tures that can extend to 30 Å, roughly corresponding to the 
size of an immunoglobulin domain (Rudd et al., 1999, 2001). 
These molecules are thought to contribute to the functional-
ity of the underlying protein in several indirect ways. For   
example, the N-linked glycans attached to the adhesion mole-
cule CD2 near the plasma membrane are thought to structurally 
restrict the protein conformation such that trans-interactions 
between CD2 and its ligand CD48 on opposing cells are 
promoted over cis-interactions between CD2 and CD48 ex-
pressed on the same cell (Dustin et al., 1996). This general 
principle is thought to apply to many of these surface glyco-
proteins including MHC and TCRs, whereby the glycans can 
prevent lateral nonspecific aggregation and provide a regular 
structural lattice for glycoprotein packing on the cell surface 
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glycosylation pattern seen in human MHCII is known to 
closely mirror the overall glycosylation pattern found in cell 
glycoproteins (Néel et al., 1987), this work suggests that 
MHCII is differentially glycosylated in active IBD and cancer.   
In strong support of this interpretation, transgenic animals ex-
pressing 1,2-fucosyltransferase have significant changes in 
cellular glycosylation patterns and develop spontaneous coli-
tis (Brown et al., 2004). The etiology of this colitis was found 
to be centered upon the T cell compartment rather than de-
fects in the mucosal barrier function. Remarkably, the GlyAg 
used in this study, PSA, has been directly implicated as being 
a key bacterial factor that contributes to the maintenance of 
gastric immune balance (Mazmanian et al., 2005, 2008). Spe-
cifically, PSA administered to gnotobiotic animals restores the 
TH1/TH2 balance to that of conventionally colonized animals 
(Mazmanian et al., 2005), and PSA elicits IL-10–producing 
T cells that show remarkable efficacy in down-regulating 
inflammation in animal models of IBD (Mazmanian et al., 
2008). Because the T cells activated by PSA appear to serve an 
antiinflammatory/tolerogenic role in the gut, our findings 
suggest that IBD-associated changes in protein glycosylation 
(Campbell et al., 2001; Brown et al., 2004) could result in   
defects in PSA presentation, leading to a failure to induce 
protective antiinflammatory IL-10–producing T cells and an 
exacerbation of gut pathology.
MATERIALS AND METHODS
Reagents and cell lines. Human Raji B cells (American Type Culture Col-
lection) were maintained in RPMI 1640 (Invitrogen) media supplemented 
with 10% FBS, penicillin, streptomycin (pen/strep), and -mercaptoethanol 
(ME). CHO cells transfected to secrete soluble human HLA-DR2 (DR2) 
were provided by K. Wucherpfennig (Dana Farber Cancer Center, Boston, 
MA; Gauthier et al., 1998) and grown in protein free medium (HyQ SFM-
4CHO; HyClone) supplemented without (untreated; UNT) and with 10 µg/ml 
KF (Cayman Chemical) or 175 µM CS (Sigma-Aldrich). The inhibitors and 
media were replaced daily. Recombinant DR2 proteins expressed with and 
without drugs present in the media (UNT-DR2, CS-DR2, and KF-DR2) 
were purified to homogeneity (>95% purity as judged by SDS-PAGE) from 
the spent culture media as previously described (Cobb et al., 2004). HEK293 
cells expressing murine TLR2 (InvivoGen) were grown in standard DME 
medium supplemented with 10% FBS. PSA was expressed by a B. fragilis variant 
that expresses only PSA in the capsule (Krinos et al., 2001) and purified to 
homogeneity, radiolabeled, fluorescently tagged with Alexa Fluor 594, and 
biotinylated as previously described (Cobb et al., 2004). Biotinylated MBPp 
(residues 84–99) and OVAp (residues 323–339) were purchased from New 
England Peptide. mAb specific for HLA-DR (clone L243) was expressed and 
purified from HB-55 B cell hybridoma supernatants using a recombinant 
protein A column (GE Healthcare) and labeled with Alexa Fluor 488 accord-
ing to the manufacturer’s protocol (Invitrogen).
Flow cytometry. For in vitro and ex vivo experiments, cells were cul-
tured for 3 d in the presence and absence of 10 µg/ml KF or 175 µM CS. 
The inhibitors and media were replaced daily. After treatment, the cells 
were  washed  in  PBS  and  resuspended  in  FACS  staining  buffer  (PBS,   
pH 7.2, 3% FBS, and 0.5% sodium azide) supplemented with either 2 µg   
Alexa Fluor 488–conjugated L243 mAb or 5 µg FITC-conjugated Phase-
olus vulgaris leucoagglutinin (PHA-L; Vector Laboratories) for 30 min on 
ice. Cells were washed twice in PBS before FACS analysis on a C6 flow 
cytometer (Accuri Cytometers). Staining primary cells from animals was 
performed using the same protocol. Intracellular cytokine staining was 
MHCII concentration, or MHCII conformational changes, 
although we cannot rule out small localized structural varia-
tions that do not affect peptide ligands.
It  is  conceivable  that  the  requirement  for  large  native 
complex N-glycans on MHCII for GlyAg binding is based 
on extending the surface area of the binding platform beyond 
that of the canonical peptide-binding groove. GlyAg and 
peptide association with MHCII is competitive and GlyAg 
presentation by APCs is dependent on HLA-DM expression 
(Cobb and Kasper, 2008; Velez et al., 2009), establishing that 
bound peptide must be removed before GlyAgs can bind. 
As a result, GlyAgs likely form contacts within the peptide-
binding groove. However, the presented form of GlyAgs ranges 
in molecular mass between 3 and 10 kD (Cobb et al., 2004; 
Cobb and Kasper, 2008), which is greater than the typical 
13–18-aa peptide found bound to MHCII. Furthermore, we 
have shown that the helical nature of the GlyAg conformation 
must  be  maintained  to  facilitate  MHCII  binding  (Kreisman   
et al., 2007). Based on the known structure of MHCII (Gauthier 
et al., 1998), it is difficult to imagine how the relatively con-
strained surface area of the peptide-binding groove alone can 
stably associate with a helical 3–10 kD polysaccharide. Given 
that complex N-glycans can be the physical size of an immuno-
globulin domain (30 Å x 10 Å x 10 Å; Rudd et al., 1999), 
inclusion of the two conserved sites for MHCII glycosylation 
could potentially add up to 600 Å2 in surface area on which 
the GlyAg molecule could associate, although the glycan array 
results show that these structures alone are insufficient for 
GlyAg binding. Our findings allow us to speculate that native 
complex N-glycans, as well as the MHCII protein backbone, 
form direct contacts with GlyAgs and that modification of 
these N-glycans destabilizes GlyAg association by removing a 
physical portion of the binding site.
This study represents the first time that the N-linked 
glycans on MHCII have been shown to play an integral role 
in antigen binding. However, in 1995 it was reported that alter-
ing the glycosylation sites in Ed resulted in changes in thymus 
selection of V7+ T cells (Ishikawa et al., 1995), suggesting that 
glycosylation can influence the binding of a subset of TCRs,   
depending on the V usage, although it remains unclear 
whether this effect was direct (i.e., the glycans participated in 
the binding) or indirect (e.g., through structural alignment of 
the binding surfaces). A few years later, the Mellins group re-
ported that creation of a novel glycosylation site at N94 in 
DRA showed severe defects in peptide antigen presentation 
(Guerra et al., 1998). It was determined that the new glycan 
site interfered with HLA-DM–catalyzed ligand exchange on 
MHCII, and thus had an indirect role in peptide binding.
The nature of glycans expressed by a given cell is depen-
dent on the expression pattern of glycosyltransferases in the 
Golgi apparatus. It is established, for example, that gastric epi-
thelial cells show varied glycosylation of MHCII as compared 
with B cells (Barrera et al., 2002). Perhaps more significantly, 
alterations in cellular protein glycosylation have been reported 
in  inflammatory  bowel  disease  (IBD)  and  colon  cancer   
patients (Campbell et al., 2001; Bodger et al., 2006). Because the JEM VOL. 208, May 9, 2011 
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Kreisman et al., 2007). In brief, 200 ng of each purified recombinant DR2 
protein (UNT-DR2, CS-DR2, or KF-DR2) was immobilized in wells of an 
Immulon 4HBX 384 well ELISA plate. 2.0 µg of either biotinylated, low 
molecular weight PSA or biotinylated MBPp was incubated in the DR2 or 
negative control FBS-blocked wells for 24 h at 37°C. For the MBPp binding, 
the binding was performed in Tris-buffered saline, pH 7.5, while PSA bind-
ing was performed in citrate-buffered saline, pH 4.5 as previously reported 
(Cobb and Kasper, 2008). Bound biotinylated ligand was quantified as de-
scribed for the coimmunoprecipitation presentation experiments using 
Eu-SA and TRF on a Victor3V counter. Statistical analyses of the resulting 
data were performed using a Student’s t test in InStat.
Lectin ELISA. The nature of N-glycans on CHO-expressed UNT-DR2, 
CS-DR2, and KF-DR2 proteins was determined by ELISA with several 
biotinylated lectins (indicated in Fig. 4, D and E; Vector Laboratories). 2 µg of   
each protein was immobilized in wells of an Immulon 4HBX 96-well ELISA 
plate and probed with 5 µg/ml of each lectin. Each protein was done in at 
least triplicate for each of the lectins. Comparisons were made by normaliz-
ing the signal to unity for the UNT-DR2 and then calculating the fold 
change in lectin binding for each of the CS-DR2 and KF-DR2.
Glycan-binding array. High-throughput glycan-binding array screening 
was performed as described previously (Paulson et al., 2006; von Gunten   
et al., 2009) by the Core H of the National Institutes of Health–funded 
Consortium for Functional Glycomics, except Alexa Fluor 488–conjugated 
PSA was used as the potential glycan binding molecule. The glycan targets 
immobilized on the array is presented in Table S1.
TLR2 activation. HEK293 cells expressing recombinant TLR2 were grown 
in 6-well plates in the presence and absence of 10 µg/ml KF or 175 µM CS 
for 3 d. On day 4, cells were transferred to a 96-well plate at 2 × 104 cells per 
well. Cells were stimulated for 12 h with either 50 µg/ml PSA, as shown pre-
viously (Wang et al., 2006), or 15 nM Pam3Cysk4. Culture supernatants were 
then analyzed for IL-8 production by sandwich ELISA according to the 
manufacturer’s protocol (BioLegend).
T cell activation (inhibitors). Mouse BM of WT C57BL/6 mice (The 
Jackson Laboratory) were differentiated into BMDCs by growing them in 
RPMI 1640 containing 10% FBS, ME, pen/strep, 15 ng/ml GM-CSF   
(Invitrogen) for 10 d. On days 7–9, BMDCs were treated with 10 µg/ml KF or 
175 µM CS. On day 10, BMDCs were collected and verified by flow cytom-
etry using CD11c-specific mAb and cultured for 24 h with and without fresh 
drugs and antigen (see Results section). On day 11, fresh naive CD4+ T cells 
were isolated from the spleens of untreated C57BL/6 mice (or OT-II mice 
for OVAp assays; The Jackson Laboratory) by positive selection using CD4+ 
magnetic  beads  (Miltenyi  Biotec)  and  verified  by  flow  cytometry  using 
CD4-specific mAb. CD4+ T cells were then added to the BMDC cultures at 
a 10:1 ratio (i.e., 10 T cells per BMDC) and the samples were incubated for 
3 d (DQ-OVA and OVAp assays) or 4 d (GlyAg assays) without the addition 
of more CS or KF. Culture supernatants were then analyzed for IFN- by 
sandwich ELISA according to the manufacturer’s protocol (BioLegend). Sta-
tistical analyses were performed using an unpaired analysis of variance with 
Bonferroni Multiple Comparisons post-test.
BMDC maturation. As described in the previous section for T cell activa-
tion, BMDCs were cultured for 3 d with and without CS and KF. Antigen-
induced  maturation  after  24  h  stimulation  was  measured  by  cell  surface 
staining and flow cytometry using FITC-conjugated mouse MHCII-specific 
mAb (clone 25–9-17; BioLegend).
MGat2 experiments. BM cells collected from WT C57BL/6 (MGat2wt) 
and B6.129-MGat2tm1Jxm/J (MGat2flox) mice (The Jackson Laboratory) were 
depleted of erythrocytes using Red Blood Cell Lysing Buffer (Sigma-Aldrich). 
Using the Neon Transfection System and the Neon 100 µl kit (Invitrogen), 5 × 
106 cells were electroporated with 6 µg pCAG-Cre (Matsuda and Cepko, 2007) 
performed after a 6-h stimulation with 10 ng/ml PMA and 500 nM ion-
omycin.  Analyses  of  FACS  data  were  performed  using  FCS  Express   
(De Novo Software).
Confocal microscopy. Raji B cells were incubated in the presence or   
absence of 10 µg/ml KF or 175 µM CS for 3 d, with fresh drug and media 
added daily. On the final day, Alexa Fluor 594–conjugated PSA was added   
to the cells. 24 h later, cells were harvested, washed, and fixed in 4% parafor-
maldehyde for 30 min on ice. The cells were washed and incubated with 
Alexa Fluor 488–conjugated L243 mAb for 30 min on ice. The cells were 
then washed and mounted on coverslips for viewing by confocal microscopy 
using an SP5 laser scanning confocal microscope (63× oil-immersion objective; 
Leica). Cross-sectional histograms of the pixel intensities were determined from 
high-resolution confocal images (n > 10 per sample) using the Leica Applica-
tion Suite software, and then used to calculate the average pixel intensities 
found within the borders of each cell (vesicular) and those found on the bor-
ders of the cells (surface) as described previously (Cobb et al., 2004). Statisti-
cal  analyses  of  surface  and  vesicular-localized  signals  were  performed 
using an unpaired analysis of variance with Bonferroni Multiple Compari-
sons post-test with GraphPad InStat software (GraphPad Software).
Antigen processing assays. PSA processing was measured as previously 
described (Cobb et al., 2004). Raji B cells (107) treated with and without 
10 µg/ml KF or 175 µM CS for 3 d before antigen exposure were cultured 
with 0.5 mg [3H]PSA for 15 h at 37°C to allow for endocytosis and process-
ing. Cells were harvested and washed with PBS, and then mechanically lysed 
by passage through a 27-gauge needle in 250 mM sucrose buffered with 25 mM 
Tris-HCl, pH 7.5. Microsomes were isolated for analysis of endocytosed 
glycoantigen by centrifugation at 100,000 g for 1 h. The pellet was resus-
pended in 25 mM Tris, pH 7.5, and 0.5 mg/ml Pronase to eliminate any in-
teractions between PSA and resident proteins for 2 h at 37°C. The resulting 
sample was then passed through a Superose 12 molecular sieve column fitted 
to an Äkta Purifier10 HPLC system (GE Healthcare) while collecting fractions. 
The fractions were analyzed by liquid scintillation counting and graphed by 
elution volume to determine the molecular size of the glycoantigen frag-
ments isolated from the vesicular compartments of Raji B cells.
Antigen presentation assays. 107 Raji B cells untreated or treated with   
10 µg/ml KF or 175 µM CS for 3 d before antigen exposure were cultured 
with 0.25 mg biotin-conjugated PSA or 0.25 mg biotin-conjugated MBPp 
for 24 h at 37°C to allow for presentation. Cells were harvested, washed, and 
digested with papain (0.1 mg/ml papain; 10 mM Tris-HCL, pH 7.5; 1 mM 
EDTA; 1% ME) to release surface-localized MHCII proteins and their inter-
acting antigens (Wiman et al., 1982). Protease inhibitor cocktail (Sigma-Aldrich) 
was added and the samples incubated in wells of ELISA plates precoated with 
either 25 µg HLA-DR–specific L243 mAb or IgG2a isotype control over-
night at 4°C. The wells were washed and incubated with europium-conjugated 
streptavidin (Eu-SA; PerkinElmer) for 45 min. The wells were washed again 
and the biotinylated PSA or MBPp present quantified by time-resolved fluo-
rescence  (TRF)  on  a Victor3V  Multilabel  Counter  using  dissociation   
enhanced fluorescence Enhancement Solution according to the manufacturer’s 
protocol (PerkinElmer). Statistical comparisons between untreated and drug-
treated samples with each antigen were performed with a student’s t test 
using InStat.
Cell viability assays. 105 Raji B cells untreated or treated with 10 µg/ml 
KF or 175 µM CS for 3 d were cultured in 200 µl of media in wells of a   
96-well plate in quadruplicate. At the end of day 3, 50 µl of culture super-
natant was removed from each culture well and combined with 50 µl of 
ATPlite reagent (PerkinElmer) for 5 min. ATP concentration was measured 
by luminescence on a  Victor3V Multilabel Counter as a measure of cell meta-
bolic activity and viability.
Binding assays. The interaction between HLA-DR2 and MBPp or PSA 
was measured exactly as previously described (Cobb and Kasper, 2008, 1052 MHC class II glycosylation in presentation of glycoantigens | Ryan et al.
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